{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:05:55Z","timestamp":1791234355898,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"publisher","award":["CFRPG3P0011"],"award-info":[{"award-number":["CFRPG3P0011"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03290-1","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:14:07Z","timestamp":1783606447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effectiveness of dual antiplatelet therapy after revascularization in diabetes and chronic limb-threatening ischemia: a target trial emulation study"],"prefix":"10.1186","volume":"25","author":[{"given":"Cheng-Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pi-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yuan","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"3290_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3686","volume":"40","author":"R Fitridge","year":"2024","unstructured":"Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt CA, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer. Diabetes Metab Res Rev. 2024;40:e3686.","journal-title":"Diabetes Metab Res Rev"},{"key":"3290_CR2","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s12325-025-03185-9","volume":"42","author":"K Islam","year":"2025","unstructured":"Islam K, Islam R, Nguyen I, Malik H, Pirzadah H, Shrestha B, et al. Diabetes mellitus and associated vascular disease: pathogenesis, complications, and evolving treatments. Adv Ther. 2025;42:2659\u201378.","journal-title":"Adv Ther"},{"key":"3290_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejvs.2019.05.006","volume":"58","author":"MS Conte","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58:1\u2013109.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"3290_CR4","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","volume":"149","author":"HL Gornik","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2024;149:e1313\u2013410.","journal-title":"Circulation"},{"key":"3290_CR5","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45:3538\u2013700.","journal-title":"Eur Heart J"},{"key":"3290_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcin.2013.05.022","volume":"7","author":"D Scheinert","year":"2014","unstructured":"Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10\u20139.","journal-title":"JACC Cardiovasc Interv"},{"key":"3290_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/CIRCULATIONAHA.114.011004","volume":"131","author":"G Tepe","year":"2015","unstructured":"Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495\u2013502.","journal-title":"Circulation"},{"key":"3290_CR8","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/0002-9149(90)90501-Q","volume":"66","author":"BJ Rensing","year":"1990","unstructured":"Rensing BJ, Hermans WR, Beatt KJ, Laarman GJ, Suryapranata H, van den Brand M, et al. Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1990;66:1039\u201344.","journal-title":"Am J Cardiol"},{"key":"3290_CR9","doi-asserted-by":"publisher","first-page":"20B","DOI":"10.1016\/0002-9149(87)90479-6","volume":"60","author":"LA Harker","year":"1987","unstructured":"Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol. 1987;60:20B-B28.","journal-title":"Am J Cardiol"},{"key":"3290_CR10","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/01.CIR.96.3.996","volume":"96","author":"MJ Post","year":"1997","unstructured":"Post MJ, de Smet BJ, van der Helm Y, Borst C, Kuntz RE. Arterial remodeling after balloon angioplasty or stenting in an atherosclerotic experimental model. Circulation. 1997;96:996\u20131003.","journal-title":"Circulation"},{"key":"3290_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/01.ATV.16.3.479","volume":"16","author":"LA Guzman","year":"1996","unstructured":"Guzman LA, Mick MJ, Arnold AM, Forudi F, Whitlow PL. Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model. Arterioscler Thromb Vasc Biol. 1996;16:479\u201387.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3290_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","volume":"286","author":"AT Hirsch","year":"2001","unstructured":"Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317\u201324.","journal-title":"JAMA"},{"key":"3290_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/life13071580","author":"HUH Virk","year":"2023","unstructured":"Virk HUH, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, et al. Dual antiplatelet therapy: a concise review for clinicians. Life. 2023. https:\/\/doi.org\/10.3390\/life13071580.","journal-title":"Life"},{"key":"3290_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050596","author":"SY Tsai","year":"2022","unstructured":"Tsai SY, Li YS, Lee CH, Cha SW, Wang YC, Su TW, et al. Mono or dual antiplatelet therapy for treating patients with peripheral artery disease after lower extremity revascularization: a systematic review and meta-analysis. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15050596.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3290_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1583\/13-4275MR.1","volume":"20","author":"FF Strobl","year":"2013","unstructured":"Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther. 2013;20:699\u2013706.","journal-title":"J Endovasc Ther"},{"key":"3290_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","volume":"52","author":"JJ Belch","year":"2010","unstructured":"Belch JJ, Dormandy J, Committee CW, Biasi GM, Cairols M, Diehm C, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825\u201333.","journal-title":"J Vasc Surg"},{"key":"3290_CR17","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382:1994\u20132004.","journal-title":"N Engl J Med"},{"key":"3290_CR18","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1001\/archinte.159.17.2041","volume":"159","author":"HG Beebe","year":"1999","unstructured":"Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041\u201350.","journal-title":"Arch Intern Med"},{"key":"3290_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.jvs.2020.08.125","volume":"73","author":"K Desai","year":"2021","unstructured":"Desai K, Han B, Kuziez L, Yan Y, Zayed MA. Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. J Vasc Surg. 2021;73:711-21 e3.","journal-title":"J Vasc Surg"},{"key":"3290_CR20","doi-asserted-by":"crossref","unstructured":"Sansosti AA, Choi B, Munoz J, Aljabban I, Morrissey NJ, O'Donnell TFX, et al. Pre-operative Cilostazol in Patients with Chronic Limb Threatening Ischaemia Associated with Improved Survival after Endovascular Revascularisation. Eur J Vasc Endovasc Surg. 2025.","DOI":"10.1016\/j.ejvs.2025.08.035"},{"key":"3290_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"key":"3290_CR22","doi-asserted-by":"publisher","first-page":"2653300","DOI":"10.1080\/07853890.2026.2653300","volume":"58","author":"CW Lin","year":"2026","unstructured":"Lin CW, Huang YY, Lin CH, Huang CH, Hung SY, Chen IW, et al. Prognostic implications of single antiplatelet therapy in individuals developing diabetic foot disease with concurrent peripheral arterial disease. Ann Med. 2026;58:2653300.","journal-title":"Ann Med"},{"key":"3290_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","volume":"147","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573\u20137.","journal-title":"Ann Intern Med"},{"key":"3290_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","volume":"334","author":"AG Cashin","year":"2025","unstructured":"Cashin AG, Hansford HJ, Hernan MA, Swanson SA, Lee H, Jones MD, et al. Transparent reporting of observational studies emulating a target trial-the TARGET statement. JAMA. 2025;334:1084\u201393.","journal-title":"JAMA"},{"key":"3290_CR25","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1093\/ndt\/gft103","volume":"28","author":"T Gremmel","year":"2013","unstructured":"Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28:2116\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"3290_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14017431.2019.1598571","volume":"53","author":"Y Wu","year":"2019","unstructured":"Wu Y, Song Y, Pan Y, Gong Y, Zhou Y. High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies. Scand Cardiovasc J. 2019;53:55\u201361.","journal-title":"Scand Cardiovasc J"},{"issue":"Suppl 1","key":"3290_CR27","first-page":"S5","volume":"121","author":"TS Lai","year":"2010","unstructured":"Lai TS, Hsu CC, Lin MH, Wu VC, Chen YM. Trends in the incidence and prevalence of end-stage kidney disease requiring dialysis in Taiwan: 2010-2018. J Formos Med Assoc. 2010;121(Suppl 1):S5\u201311.","journal-title":"J Formos Med Assoc"},{"key":"3290_CR28","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","volume":"135","author":"CN Hess","year":"2017","unstructured":"Hess CN, Norgren L, Ansel GM, Capell WH, Fletcher JP, Fowkes FGR, et al. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation. 2017;135:2534\u201355.","journal-title":"Circulation"},{"key":"3290_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jvs.2018.06.193","volume":"68","author":"AZ Fashandi","year":"2018","unstructured":"Fashandi AZ, Mehaffey JH, Hawkins RB, Kron IL, Upchurch GR Jr., Robinson WP. Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. J Vasc Surg. 2018;68:1817\u201323.","journal-title":"J Vasc Surg"},{"key":"3290_CR30","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","volume":"5","author":"RR Holman","year":"2017","unstructured":"Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5:877\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3290_CR31","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","volume":"382","author":"DJ Maron","year":"2020","unstructured":"Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O\u2019Brien SM, Boden WE, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382:1395\u2013407.","journal-title":"N Engl J Med"},{"key":"3290_CR32","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1177\/15266028241241248","volume":"32","author":"Q Tan","year":"2025","unstructured":"Tan Q, Chen Z, Wu H, Wang H, Chen J, Lai K, et al. A systematic review and meta-analysis of efficacy and safety of cilostazol prescription in patients with femoropopliteal peripheral artery disease after endovascular therapy. J Endovasc Ther. 2025;32:1872\u201388.","journal-title":"J Endovasc Ther"},{"key":"3290_CR33","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jvs.2024.01.010","volume":"80","author":"G Galyfos","year":"2024","unstructured":"Galyfos G, Chamzin A, Saliaris K, Theodorou P, Konstantinou K, Sigala F, et al. The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease. J Vasc Surg. 2024;80:279\u201387.","journal-title":"J Vasc Surg"},{"key":"3290_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","volume":"53","author":"Y Soga","year":"2009","unstructured":"Soga Y, Yokoi H, Kawasaki T, Nakashima H, Tsurugida M, Hikichi Y, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol. 2009;53:48\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"3290_CR35","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","volume":"127","author":"O Iida","year":"2013","unstructured":"Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013;127:2307\u201315.","journal-title":"Circulation"},{"key":"3290_CR36","first-page":"1329","volume":"348","author":"CS Committee","year":"1996","unstructured":"Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee Lancet. 1996;348:1329\u201339.","journal-title":"CAPRIE Steering Committee Lancet"},{"key":"3290_CR37","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2174\/1570161118666200820141131","volume":"19","author":"M De Carlo","year":"2021","unstructured":"De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C. Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis. Curr Vasc Pharmacol. 2021;19:542\u201355.","journal-title":"Curr Vasc Pharmacol"},{"key":"3290_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/00207454.2012.744308","volume":"123","author":"MS Hasan","year":"2013","unstructured":"Hasan MS, Basri HB, Hin LP, Stanslas J. Genetic polymorphisms and drug interactions leading to clopidogrel resistance: why the Asian population requires special attention. Int J Neurosci. 2013;123:143\u201354.","journal-title":"Int J Neurosci"},{"key":"3290_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052593","author":"M Sohn","year":"2024","unstructured":"Sohn M, Lim S. The role of Cilostazol, a phosphodiesterase-3 inhibitor, in the development of atherosclerosis and vascular biology: a review with meta-analysis. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25052593.","journal-title":"Int J Mol Sci"},{"key":"3290_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060938","author":"JL Lin","year":"2022","unstructured":"Lin JL, Tseng WK, Lee PT, Lee CH, Tseng SY, Chen PW, et al. A randomized controlled trial evaluating outcome impact of Cilostazol in patients with coronary artery disease or at a high risk of cardiovascular disease. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12060938.","journal-title":"J Pers Med"},{"key":"3290_CR41","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/dom.13667","volume":"21","author":"DH Lee","year":"2019","unstructured":"Lee DH, Chun EJ, Oh TJ, Kim KM, Moon JH, Choi SH, et al. Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes Obes Metab. 2019;21:1409\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"3290_CR42","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/1753-0407.13300","volume":"14","author":"M Sohn","year":"2022","unstructured":"Sohn M, Chun EJ, Lim S. Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. J Diabetes. 2022;14:524\u201331.","journal-title":"J Diabetes"},{"key":"3290_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.atherosclerosis.2011.09.048","volume":"220","author":"DF Geng","year":"2012","unstructured":"Geng DF, Deng J, Jin DM, Wu W, Wang JF. Effect of cilostazol on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012;220:177\u201383.","journal-title":"Atherosclerosis"},{"key":"3290_CR44","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1111\/dom.14147","volume":"22","author":"DH Lee","year":"2020","unstructured":"Lee DH, Chun EJ, Moon JH, Yun HM, Lim S. Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: the FANCY study. Diabetes Obes Metab. 2020;22:2257\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"3290_CR45","first-page":"S17","volume":"17","author":"KL Jablonski","year":"2013","unstructured":"Jablonski KL, Chonchol M. Vascular calcification in end-stage renal disease. Hemodial Int. 2013;17(Suppl 1):S17-21.","journal-title":"Hemodial Int"},{"key":"3290_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrneph.2010.157","volume":"7","author":"V Kon","year":"2011","unstructured":"Kon V, Linton MF, Fazio S. Atherosclerosis in chronic kidney disease: the role of macrophages. Nat Rev Nephrol. 2011;7:45\u201354.","journal-title":"Nat Rev Nephrol"},{"key":"3290_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123661","volume":"477","author":"J Koge","year":"2025","unstructured":"Koge J, Toyoda K, Koga M, Fukuda-Doi M, Uchiyama S, Kimura K, et al. Effect of renal function on dual antiplatelet therapy using cilostazol for stroke prevention: a CSPS.com trial post hoc analysis. J Neurol Sci. 2025;477:123661.","journal-title":"J Neurol Sci"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03290-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:02:15Z","timestamp":1790982135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03290-1","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving human participants were reviewed and approved by The Institutional Review Board of Chang Gung Memorial Hospital, Taiwan (No. 202301438B0). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"296"}}